This antibody was recently successfully implemented in a digital enzyme-linked immunosorbent assay (ELISA) platform and able to detect attomolar concentrations of Tau protein, thereby unlocking the potential of Tau as a serum-based AD biomarker [98]. This evidence concerns the gene MAPT and Alzheimer disease.